Home

About

Med Services

Medical Departments

Clinics and Institutes

Central Laboratory

Health Services

Centers of Excellence

News

Press Releases

Press Clips

Medical Forefront

Publications

Windows on Hadassah

Treatment In Israel

Contact

Home > Physicians, Researchers

Physicians, Researchers

Dr. Diana Libster, MD

Department of Hematology

Hadassah University Hospital

Mount Scopus, Jerusalem

Personal Data

Date of Birth: January 12, 1952, Ukraine

1991 - Immigration to Israel

Address: Elazar Kashany Street 4/13, Armon Hanatziv, Jerusalem 93806

Tel/Fax:: 972-2-672-1287

Medical Training

1968-1974 Medical School, Kursk University, Russia

1974-1975 Internship, University Hospital, Donezk, Ukraine

1975-1977 Residency, Internal Medicine, University Hospital, Donezk, Ukraine

1977-1979 Residency, Institute of Hematology and Blood Transfusion, Moscow, Russia

1991 Course for new immigrant physicians, Hadassah University Hospital, Jerusalem, Israel

1992-1993 Residency in Hematology Department, Hadassah University Hospital, Jerusalem

1993-1994 Residency in Internal Medicine Department, Hadassah University Hospital, Jerusalem, Israel

Board Certifications

1996 - Israel Board of Internal Medicine

1998 - Israel Board of Hematology

Professional Societies

Israel Medical Association

Israel Medical Association of Internal Medicine

Israel Medical Association of Hematology

American Society of Hematology

Past Employment

1980-1990 - Attending Physician, Hematology Consultant, Department of Internal Medicine, City Hospital, Kvivoy-Rog; Ukraine

1980-1990 - Hematology Specialist; Senior Hematology consultant, Hematology Center, Kvivoy-Rog, Ukraine

Hadassah Hospital Appointment

1995 - Senior Hematologist, Hematology Day Care Center, Hadassah, Mt. Scopus

Consultant

1999- Home Care Physician and Consultant, Klalit Health Services, Home and Palliative Service

2002-2006 Hematology Clinic Consultant, Sheich Jarrah Clinic, Klalit Health Services

Clinical Activities

Hadassah Mt. Scopus Campus

1995 - Day Care Clinic

1995 - Out patient Clinic

1995 - Hospitalized patients

Hadassah Ein Kerem Campus

1993 - Hospitalized patients

1995-2002 - Day Care Clinic

List of Publications

1. Gillis, S., Lossos, IS., Libster, D., Paltiel, O., Polliack, A. Stanford V regimen in advanced stage (III-IV) Hodgkin's diseases. Blood 92(10 suppl 1): 236B-236B, 1998.

2. Steiner, H., Polliack, A., Kimchi-Sarfaty, C., Libster, D., Fibach, E., Rund, D. Differences in Rhodamine 123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug resistance gene activity. Ann Hematol, 76(5): 189-194, 1998.

3. Libster, D., Heled, Y., Shapiro, Y., Epstein Y. Physiological aspects of women in combat. Harefuah 137(11): 521-525, 1999. (Hebrew)

4. Da’as, N., Libster, D., Paltiel, O., Cohen, Y., Polliack, A. Treatment of early stage Hodgkin’s disease with 2-4 cycles of ABVD with or without radiotherapy. 5th International Symposium on Hodgkin’s Lymphoma. Colon, Germany. (Abstract # HLA174) 2001.

5. Da’as, N., Libster, D., Paltiel, O., Cohen, A., Cohen, Y., Polliack, A. Stanford V Regimen for advanced Hodgkin’s disease. Leuk Lymphoma 42(2 supp.2):63, 2001.

6. Cohen, Y., Gillis, S., Da’as, N., Libster, D., Polliack, A. Unusual presentation of acute myeloblastic leukemia with extreme hyperleukocytosis as an acute myocardial infarction secondary to leukostasis. 6th Annual Meeting of the European Hematology Association (EHA-6). Hematology Journal 1(1): 119, 2001.

7. Cohen, Y., Ben Yehuda, D., Da’as, N., Libster D., Berebi, A., Polliack, A. Association between treatment with immunosuppressive antitumor agents, fludarabine/rituximab and rapid progression/transformation of indolent lymphomas or CLL. 6th Annual Meeting of the European Hematology Association (EHA-6). Hematology Journal (suppl) vol.1:page 46, (poster 139), 2001.

8. Polliack, A., Cohen, Y., Da’as, N,. Libster, D., Shvidel, L., Klepfish, A., Shtalrid, M., Haran, M., Berrebi, A. Fludarabine (FLU) – containing regimen and Rituximab (RI) as primary therapy with curative intent for younger patients with progressive and advanced B-CLL: High rate of initial response including molecular remissions. Blood 98(11):364A-364A, 2001.

9. Cohen, Y., Da’as, N., Libster, D., Polliack, A. Rituximab (RI) or RI-containing regimens induce sustained complete remission (CR) in extranodal lymphoma (LY) and relapsed high grade LY: report of six unusual cases. Blood 98(11b): 239B-239B, 2001.

10. Cohen, Y., Da’as N., Libster, D., Gillon, D., Polliack, A. Large B-cell lymphoma manifesting as an invasive cardiac mass: sustained local remission after combination of Methotrexate and Rituximab. Leuk Lymphoma 43(7):1458-1487, 2002.

11. Cohen, Y., Da’as, N., Libster, D., Amir, G., Berrebi, A., Polliack, A. Large- cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine and rituximab containing regimens: natural history or therapy-related complication? Eur J of Hematol, 68(2):80-83, 2002.

12. Dann, EJ., Haim, N., Kirshbaum, MH., Libster, D., Israel, O., Rowe, JM., Epelbaum, R. Tailored BEACOPP regimen for standard and high risk Hodgkin lymphoma based on early response to Ga67 scintigraphy and the international prognostic score for advanced disease (IPS). Blood 98 (11): 240B-240B, 2001.

13. Dann, EJ; Haim, N; Ben Shachar, M; Kirschbaum, M; Goor, O; Libster, D; Israel, O; Rowe, JM; Epelbaum, R. Tailored BEACOPP regimen for unfavorable Hodgkin lymphoma (HD) based on early response to Ga-67/F(18)dg scintigraphy and international prognostic score for advanced disease (IPS). Blood 100 (11): 779A-779A, 2002.

14. Cukierman, T., Gatt, ME., Libster, D., Goldschmidt, N., Matzner, Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 43(9): 1865-1868, 2002.

15. Cohen, AM., Polliack, A., Ben-Bassat, I., Avigdor, A., Bennett, M,.Libster, D. et al. Results of a phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicular lymphoma (FL): the Israel Cooperative Lymphoma Group. Blood 100(11): 360A-360A, 2002.

16. Cohen, Y., Libster, D., Da'as, N., Polliack, A. Re-treatment with Rituximab as a single agent induces sustained remission in a patient with relapsed advanced follicular lymphoma with multiple extranodal sites of involvement. The 7th annual meeting of the European Hematology Association (EHA7 – abstract # 1280).

17. Cohen, Y., Libster, D., Da'as, N., Amir, G., Polliack, A. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. Hematol J. 4(2):151-3, 2003.

18. Cohen, Y., Libster D., Amir, G., Hiller, N., Da'as, N., Ben Yehuda, D., Polliack, A. Primary ALK positive anaplastic large cell lymphoma of the pancreas. Leuk Lymphoma 44(1):205-207, 2003.

19. Gatt, ME., Libster, D., Leibowitz, D., Matzner, Y. Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication. Ann Hematol 82:136-138, 2003.

20. Cohen, Y., Libster, D., Da'as, N., Amir, G., Polliack, A. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. Hematol Journal 4 (2): 151-153, 2003.

21. Dann, EJ., Haim, N., Ben Shachar, M., Kirschbaum, MH., Goor, O., Libster, D., Gaitini, D., Bar Shalom, R., Rowe, JM. Tailoring chemotherapy regimen for standard and high risk Hodgkin lymphoma(Hd) based on early response to Ga67/F(18)DG scintigraphy and international prognostic score (IPS) for advanced disease. A report of 76 patients treated in single institution. Blood 102 (11):638A-638A, 2003.

22. Stepensky P., Prus, D., Libster, D., Amir, G., Weintraub, M., Levin, M., Urieli- Shoval S. Expression of serum amyloid A, a major acute phase protein, in human Hodgkin and non-Hodgkin lymphoma tissues. Blood 102(11): 269B-270B, 2003.

23. Gural A., Libster, D., Da'as, N., Dann, E., Epelbaum, R., Haim, N. Paltiel, O., Polliack, A. Short term duration chemotherapy with AABVD followed by involved field radiation is highly effective therapy for early stage Hodgkin's disease. Eur J Haematol 73 (suppl 65):E05:38, 2004.

24. Avigdor A, Bulvik S, Shemtov N, Levi I, Berkowicz M, Ben-Yehuda D, Blickstein D, Goldschmidt N, Gural A, Kornberg A, Libster D, Merkel D, Naparstek E, Raanani P, Roth B, Volchek Y, Nagler A, Ben-Bassat I, Polliack A . A pilot study of combined escalated BEACOPP-ABVD therapy for advanced Hodgkin's lymphoma patients with high IPS score: The Israel Cooperative Lymphoma Group. Blood 104 (11): 228B – 228B, 2004.

25. Levin, M., Libster, D. Allergic reaction to chlorambucil in chronic lymphocytic leukemia presenting with fever and lymphadenopathy. Leuk Lymphoma 46: 1195-1197, 2005.

26. Spectre, G., Libster, D., Grisariu, S., Da'as, N., Gimon, Z., Paltiel, O. Surgical complications in patients treated with chemotherapy for gastric diffuse large B cell lymphoma. Blood 106 (11): 263B-263B, 2005.

27. Dann EJ, Bar Shalom R, Haim N, Tamir A, Ben Shachar M, Avivi I, Zuckerman T, Kirschbaum M, Goor O, Libster D, Rowe JM, Apelbaum R . Risk adapted BEACOPP regimen based on early scintigraphy can reduce the cumulative dose of chemotherapy for standard and high risk Hodgkin lymphoma (HD) with no impairment of outcome. Blood 106 (11): 240A – 240A, 2005.

28. Dann E, Haim N, Bar-Shalom R, Ben-Schachar M, Kirschbaum M, Goor O, Libster D, Gaitini D, Rowe J, Epelbaum R . Use of early interim GA67 or hybrid PET/CT scintigraphy and international prognostic score (IPS) for tainoring chemotherapy regimen of standard and high risk Hodgkin lymphoma (HD) . Annals of Oncology (Suppl. 5): 146 – 146, 2005.

29. Libster D, Aserin A, Garti N. A novel dispersion method comprising a nucleating agent solubilized in a microemulsion, in polymeric matrix I. Dispersion method and polymer characterization. J Colloid Interface Sci.; 299(1):172-81, 2006.